help button home button
AJRCCM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

Published ahead of print on July 5, 2007, doi:10.1164/rccm.200702-291OC
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
200702-291OCv1
176/7/667    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chatterjee, A.
Right arrow Articles by Catravas, J. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chatterjee, A.
Right arrow Articles by Catravas, J. D.
American Journal of Respiratory and Critical Care Medicine Vol 176. pp. 667-675, (2007)
© 2007 American Thoracic Society
doi: 10.1164/rccm.200702-291OC


Original Article

Heat Shock Protein 90 Inhibitors Prolong Survival, Attenuate Inflammation, and Reduce Lung Injury in Murine Sepsis

Anuran Chatterjee1, Christiana Dimitropoulou2, Fotios Drakopanayiotakis1, Galina Antonova1, Connie Snead1, Joseph Cannon3, Richard C. Venema1,4 and John D. Catravas1,2

1 Program in Pulmonary Vascular Disease, Vascular Biology Center; 2 Department of Pharmacology and Toxicology; 3 Inflammation Core Laboratory, School of Allied Health Sciences; and 4 Department of Pediatrics, Medical College of Georgia, Augusta, Georgia

Correspondence and requests for reprints should be addressed to John D. Catravas, Ph.D., Vascular Biology Center, Medical College of Georgia, Augusta, GA 30912-2500. E-mail: jcatrava{at}mcg.edu

Rationale: Severe sepsis is the leading cause of death for patients in intensive care units. Patients with severe sepsis develop multiple organ failure, including acute lung injury (ALI), resulting from a deregulated inflammatory response. Inhibitors of the ubiquitous chaperone, heat shock protein 90 (Hsp90), block the activity of certain proinflammatory mediators in vitro. We hypothesized that Hsp90 inhibitors may ameliorate the inflammation and ALI associated with severe sepsis.

Objectives: To test the hypothesis that Hsp90 inhibitors prolong survival, attenuate inflammation, and reduce lung injury in a murine model of sepsis.

Methods: Male C57BL/6 mice received either one of two Hsp90 inhibitors, radicicol or 17-allylaminodemethoxygeldanamycin (17-AAG), 24, 12, 6, and 0 hours before receiving a lethal dose of endotoxin (6.75 x 104 endotoxin units/g body weight). Outcomes included survival and parameters of systemic inflammation (plasma neutrophil, cytokine, chemokine, and nitrite/nitrate levels), pulmonary inflammation (lung nuclear factor-{kappa}B and myeloperoxidase activities, inducible nitric oxide synthase expression, inducible nitric oxide synthase–Hsp90 complex formation, and leukocyte infiltration), and lung injury (pulmonary capillary leak and lung function).

Measurements and Main Results: Mice pretreated with vehicle and receiving endotoxin exhibited 100% 24-hour lethality, a dramatic increase in all parameters of systemic and pulmonary inflammation, increased capillary leak, and reduced lung function. Compared with them, mice receiving either radicicol or 17-AAG before endotoxin exhibited prolonged survival, reduced or abolished increases in systemic and pulmonary inflammatory parameters, attenuated capillary leak, and restored, normal lung function.

Conclusions: Hsp90 inhibitors may offer a new pharmacological tool in the management of severe sepsis and severe sepsis–induced ALI.

Key Words: Hsp90 inhibitors • sepsis • acute lung injury


AT A GLANCE COMMENTARY

Scientific Knowledge on the Subject
Patients with severe sepsis develop multiple organ failure, including acute lung injury, resulting from a deregulated inflammatory response. Inhibitors of heat shock protein 90 (Hsp90) block the activity of certain proinflammatory mediators in vitro.

What This Study Adds to the Field
Hsp90 inhibitors prolong survival, reduce or abolish systemic and pulmonary inflammation, and restore normal lung function in a murine model of sepsis.

 



This article has been cited by other articles:


Home page
Am. J. Respir. Cell Mol. Bio.Home page
A. Antonov, C. Snead, B. Gorshkov, G. N. Antonova, A. D. Verin, and J. D. Catravas
Heat Shock Protein 90 Inhibitors Protect and Restore Pulmonary Endothelial Barrier Function
Am. J. Respir. Cell Mol. Biol., November 1, 2008; 39(5): 551 - 559.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
R. A. Fowler, N. K. J. Adhikari, D. C. Scales, W. L. Lee, and G. D. Rubenfeld
Update in Critical Care 2007
Am. J. Respir. Crit. Care Med., April 15, 2008; 177(8): 808 - 819.
[Full Text] [PDF]


Home page
Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
A. Chatterjee, C. Snead, G. Yetik-Anacak, G. Antonova, J. Zeng, and J. D. Catravas
Heat shock protein 90 inhibitors attenuate LPS-induced endothelial hyperpermeability
Am J Physiol Lung Cell Mol Physiol, April 1, 2008; 294(4): L755 - L763.
[Abstract] [Full Text] [PDF]


Home page
J ANIM SCIHome page
R. A. Frost and C. H. Lang
Regulation of muscle growth by pathogen-associated molecules
J Anim Sci, April 1, 2008; 86(14_suppl): E84 - E93.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Proc. Am. Thorac. Soc. Am. J. Respir. Cell Mol. Biol.
Copyright © 2007 American Thoracic Society
  ATS Clinical Skills Tests